
20 years in structural biology software development, zebrafish genome editing, high throughput imaging, and multi-site management of reverse translational operations. Former: UVic, University of Toronto, UHN, CAN-BIND, St. Michael's Hospital.

Former leadership at Novartis, Takeda, and Alexion — the last acquired by AstraZeneca for $39B. Leads global pharma BD and strategic R&D collaborations. Dual doctorate in science and law (UCL/Queen Mary) with Harvard Business School certifications

Professor of Genomics, Proteomics &
Biomedical AI at the University of Calgary. Serial
life science entrepreneur. Leads multi-omic AI
transformation pipeline. Biomedical AI specialist with global outsourcing connections, previous leadership positions at Edinburgh & Gdansk